Meridian Bioscience logo
Meridian Bioscience VIVO
report update icon

Quarterly report 2023-Q1
added 05-16-2026

Meridian Bioscience Financial Statements 2022-2007 | VIVO

Annual Financial Statements Meridian Bioscience

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Market Cap

1.38 B 882 M 801 M 416 M 724 M 563 M 681 M 751 M 573 M 886 M 650 M 575 M - - - -

Shares

43.6 M 43.3 M 42.9 M 42.6 M 42.3 M 42.2 M 42 M 41.7 M 41.5 M 41.2 M 41.1 M 40.7 M 40.5 M 40.4 M 40.1 M -

Historical Prices

31.8 20.4 18.7 9.77 17.1 13.3 16.2 18 13.8 21.5 15.8 14.1

Net Income

42.5 M 71.4 M 46.2 M 24.4 M 8.11 M 6.3 M 6.28 M 8.89 M 7.9 M 7.43 M 8.47 M 6.58 M 6.02 M 8.92 M 30.2 M -

Revenue

333 M 318 M 254 M 201 M 51.5 M 52.3 M 46.8 M 195 M 189 M 189 M 174 M 160 M - - - -

Cost of Revenue

145 M 117 M 97.4 M 82.3 M 82.5 M 76.5 M 68.9 M - - - - - - - - -

Gross Profit

188 M 201 M 156 M 119 M 31.8 M 32 M 29 M 31.6 M 29.2 M 28 M 28.8 M 24.5 M 23.5 M 25.4 M 86.5 M -

Operating Income

54.4 M 93 M 61.3 M 32.7 M 31.6 M 37.4 M 51.4 M 56.1 M 52.4 M 57.3 M 49.3 M 40 M 41.1 M 48.8 M 44.4 M -

Interest Expense

1.19 M 1.88 M 2.63 M 1.94 M 1.52 M 1.64 M 897 K -1.02 M -309 K 4 K 378 K 352 K 138 K 88 K 109 K -

EBITDA

70.9 M 108 M 74.9 M 42.7 M 40.3 M 46.5 M 59.1 M 62.7 M 59.7 M 64.5 M 55.9 M 45.9 M 45.8 M 53.1 M 47.2 M -

Operating Expenses

134 M 108 M 94.9 M 86 M 99.4 M 86.9 M 75.8 M 65.8 M 64.9 M 63.7 M 59.8 M 58.4 M 47.6 M 43.7 M 42.1 M -

General and Administrative Expenses

57.1 M 49.5 M 44.3 M 34 M 35.8 M 31.1 M 29.4 M 27.6 M 27.4 M 30.5 M 26.4 M 24.9 M 19.7 M 17.1 M 17.2 M -

All numbers in USD currency

Quarterly Income Statement Meridian Bioscience

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3

Shares

43.9 M 43.9 M 43.6 M 43.5 M 43.4 M 43.4 M 43.3 M 43.2 M 43.1 M 43.1 M 42.8 M 42.8 M 42.8 M 42.8 M 42.6 M 42.5 M 42.4 M 42.4 M 42.3 M 42.3 M 42.3 M 42.3 M 42.2 M 42.2 M 42.2 M 42.2 M 42.1 M 42.1 M 41.9 M 41.9 M 41.7 M 41.7 M 41.6 M 41.6 M 41.5 M 41.5 M 41.4 M 41.4 M 41.3 M 41.3 M 41.1 M 41.1 M 41.1 M 41.1 M 41.1 M 41.1 M 40.7 M 40.7 M 40.6 M 40.5 M

Net Income

-29.8 M -29.8 M -7.34 M 28.8 M 15.3 M 15.3 M 11.7 M 26.3 M 26.8 M 26.8 M 27.5 M 9.36 M 2.83 M 2.83 M 5.08 M 7.09 M 8.11 M 8.11 M 6.82 M 5.29 M 6.3 M 6.3 M 240 K 9.31 M 6.28 M 6.28 M 8.75 M 9.09 M 8.89 M 8.89 M 9.1 M 10.1 M 7.9 M 7.9 M 8.84 M 10.3 M 7.43 M 7.43 M 10.2 M 10.2 M 8.47 M 8.47 M 8.59 M 9.63 M 6.58 M 6.58 M 6.84 M 7.26 M 6.02 M 6.42 M

Revenue

56.9 M 56.9 M 67.8 M 111 M 88.3 M 88.3 M 63.5 M 85.3 M 92.9 M 92.9 M 84.8 M 57.3 M 47.4 M 47.4 M 48.4 M 50.2 M 51.5 M 51.5 M 51.7 M 51.7 M 56.5 M 52.3 M 49.7 M 50.1 M 54.1 M 46.8 M 47 M 50.7 M 46.8 M 47.2 M 47.1 M 48.2 M 47.2 M 48 M 46.7 M 47.2 M 48 M 44.8 M 49 M 47.1 M 44.8 M 45.4 M 43.5 M 41.9 M 45.4 M 40.1 M 41.3 M 40.1 M 40.3 M -

Cost of Revenue

25.4 M 25.4 M 31 M 42.8 M 39.2 M 39.2 M 26.4 M 27.5 M 31.4 M 31.4 M 28.9 M 22.8 M 20 M 19.8 M 20.2 M 20.9 M 19.9 M 19.9 M 19.8 M 19.8 M 19.9 M 20.3 M 57.4 M 19 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

31.5 M 31.5 M 36.7 M 68.5 M 49.2 M 49.2 M 37.1 M 57.8 M 61.5 M 61.5 M 55.9 M 34.5 M 27.4 M 27.7 M 28.3 M 29.3 M 31.6 M 31.8 M 32 M 34.6 M 31.8 M 32 M 31.2 M 33.5 M 29.4 M 29 M 32.9 M 33.6 M 31.6 M 31.6 M 30.3 M 32.5 M 29.2 M 29.2 M 29.2 M 31.6 M 28 M 28 M 30.6 M 30.7 M 28.8 M 28.8 M 27.6 M 29.8 M 24.7 M 24.5 M 25.4 M 26.3 M 23.6 M 21.7 M

Operating Income

-28.1 M -28.1 M -6.68 M 36.1 M 20.3 M 20.3 M 15.7 M 34.2 M 34.7 M 34.7 M 34.7 M 11.8 M 5.39 M 5.39 M 6.46 M 9.84 M 10.6 M 10.6 M 8.74 M 7.68 M 8.06 M 8.06 M 4.3 M 14.2 M 10.1 M 10.1 M 13.7 M 15.2 M 13.6 M 13.6 M 14.4 M 15.7 M 12.7 M 12.7 M 13.1 M 15.7 M 11.6 M 11.6 M 15.7 M 15.3 M 13.1 M 13.1 M 12.6 M 14.8 M 9.8 M 9.8 M 10.1 M 11 M 9.09 M 9.78 M

Interest Expense

148 K 148 K 256 K 341 K 372 K 372 K 444 K 472 K 534 K 534 K 703 K 532 K 767 K 767 K 448 K 347 K 363 K 363 K 375 K 379 K 395 K 395 K 407 K 408 K 423 K 423 K 427 K 43 K 96 K 96 K -99 K -211 K -582 K -582 K -257 K -28 K -220 K -220 K -160 K 257 K 128 K 128 K 31 K -43 K 316 K 316 K 36 K 118 K 203 K -9 K

EBITDA

-26.5 M -26.5 M -1.67 M 39.5 M 22 M 22 M 20.4 M 37.3 M 36.2 M 36.2 M 38.4 M 14.2 M 6.61 M 6.61 M 10.4 M 12.4 M 11.8 M 11.8 M 12.1 M 9.91 M 9.21 M 9.21 M 7.56 M 16.3 M 11.2 M 11.2 M 16.6 M 16.9 M 14.5 M 14.5 M 17 M 17.6 M 13.6 M 13.6 M 15.8 M 17.4 M 12.5 M 12.5 M 18.2 M 16.9 M 13.9 M 13.9 M 15.3 M 16.6 M 10.7 M 10.7 M 12.7 M 12.7 M 9.94 M 12.1 M

Operating Expenses

59.6 M 59.6 M 43.4 M 32.3 M 28.9 M 28.9 M 21.4 M 23.6 M 26.9 M 26.9 M 21.2 M 22.7 M 22 M 22.3 M 21.8 M 19.5 M 21 M 21 M 23.2 M 26.9 M 23.7 M 23.9 M 26.9 M 19.3 M 19.4 M 19 M 19.2 M 18.4 M 18 M 18 M 15.9 M 16.8 M 16.6 M 16.6 M 16.1 M 15.9 M 16.4 M 16.4 M 14.9 M 15.5 M 15.7 M 15.7 M 15 M 14.9 M 14.9 M 14.7 M 15.3 M 15.3 M 14.5 M -

General and Administrative Expenses

11.1 M 11.1 M 13.1 M 18.6 M 14.7 M 14.7 M 12 M 12.9 M 11.9 M 11.9 M 12.4 M 10.5 M 8.76 M 8.98 M 8 M 7.39 M 8.9 M 8.9 M 8.38 M 9.11 M 8.9 M 9.2 M 8.47 M 7.43 M 8.45 M 7.74 M 7.54 M 6.88 M 8.17 M 8.17 M 6.54 M 6.94 M 7.38 M 7.38 M 6.72 M 6.28 M 7.55 M 7.55 M 6.78 M 7.21 M 7.5 M 7.5 M 6.16 M 6.43 M 6.64 M 6.64 M 6.44 M 5.64 M 6.52 M 4.87 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Meridian Bioscience VIVO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Meridian Bioscience plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA